Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07148414 · ClinicalTrials.gov registry record · Phase 2
A Study of SPY072 in Rheumatic Disease
A Phase 2 study of Rheumatoid Arthritis and Psoriatic Arthritis, sponsored by Spyre Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 285
- Enrollment target
- 20
- Study locations
NCT07148414: Recruiting Phase 2 study of Rheumatoid Arthritis and Psoriatic Arthritis, sponsored by Spyre Therapeutics.
NCT07148414 is a Phase 2 study of Rheumatoid Arthritis and Psoriatic Arthritis that is actively recruiting participants, run by Spyre Therapeutics. The registered enrollment target is 285 participants, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07148414, a Phase 2 study of Rheumatoid Arthritis and Psoriatic Arthritis, is actively recruiting participants, sponsored by Spyre Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 285 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center, double-blind, placebo-controlled, Phase 2, proof-of-concept basket study with the goal of assessing the efficacy and safety of SPY072 compared to placebo in adults (aged ≥18 years) with rheumatic disease (RD).
Primary Outcome
The score is calculated based on the number of tender and swollen joints out of 28 assessed (TJC28 and SJC28), a measure of inflammation in the blood (c-reactive protein, CRP), and the subject's overall assessment of their health (patient global assessment). Scores range from 0-10. Higher scores indicate greater disease activity.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SPY002-072
Study Locations (20)
California
- Site 114 - Chula Vista
- Site 111 - Covina
- Site 108 - Tujunga
- Site 112 - Upland
- Site 107 - Whittier
Florida
- Site 109 - Hialeah
- Site 106 - Ormond Beach
- Site 110 - Tampa
Texas
- Site 105 - Corpus Christi
- Site 103 - Tomball
- Site 102 - Tomball
Plovdiv
- Site 506 - Plovdiv
- Site 505 - Plovdiv
Arizona
- Site 113 - Avondale
Pennsylvania
- Site 104 - Duncansville
Lovech
- Site 503 - Lovech
Pleven
- Site 502 - Pleven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2025-08-21 |
| Est. Completion | 2028-03-31 |
| Phase | Phase 2 |
What NCT07148414 shows while recruiting
NCT07148414 is an interventional study that assigns participants to a tested intervention. The registered 285 participants enrollment target is mid-sized for trials with a published cap, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (94% lower).
The record links to 8 conditions, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07148414 names 20 study sites across 11 states, led by California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT07148414 about?
NCT07148414 is a clinical study titled "A Study of SPY072 in Rheumatic Disease". This is a multi-center, double-blind, placebo-controlled, Phase 2, proof-of-concept basket study with the goal of assessing the efficacy and safety of SPY072 compared to placebo in adults (aged ≥18 years) with rheumatic disease (RD).
What is the current status of trial NCT07148414?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 285 participants. The study started on 2025-08-21. Estimated completion is 2028-03-31.
What conditions does trial NCT07148414 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatic Diseases, Axial Spondyloarthritis, Rheumatologic Disease.
What interventions are being tested in trial NCT07148414?
The interventions under investigation include: Placebo (DRUG), SPY002-072 (DRUG).
Who is sponsoring clinical trial NCT07148414?
This trial is sponsored by Spyre Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07148414 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07148414's enrollment target sits among peer trials
285 63rd of 197 higher than 135 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dynamic Treatment Regiments for Glucocorticoid Tapering
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
RECRUITING · Phase 2
-
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03412877 · 285 participants · Phase 2
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- NCT04537936 · 285 participants · NA
Psychotherapy Intervention for Latinos With Adv Cancer
- NCT04965675 · 285 participants · Phase 3
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
- NCT05320835 · 285 participants · NA
A Setting Focus Overdose Prevention Intervention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI